More News of Interest

Philips to Introduce Latest Advancements In Digital Pathology at the European Congress of Pathology 2020 Virtual Event

Building on its strong portfolio to support oncology clinical decision-making, the company brings together the power of imaging, pathology, genomics, and longitudinal data with insights from artificial intelligence, to empower clinicians to deliver clear care pathways with predictable outcomes for every patient.

Zenith Award from American Association for Respiratory Care for Support of Respiratory Therapists Is Awarded to Vapotherm

Award celebrates excellence in support and quality as chosen by AARC member votes

Attune Medical Major Milestones: Including ensoETM in Cardiac Ablation Procedures Published Study and $4 Mil Convertible Note Closing

Dr. Mark Gallagher (St. George’s University Hospital, London UK) evaluated the use of the ensoETM in cardiac ablation procedures to ascertain whether using the esophageal space for temperature management could have the potential to decrease collateral thermal injury related to radio-frequency (RF) ablation for the treatment of atrial fibrillation.

Signia Introduces World’s First ‘Face Mask Mode’ for Hearing Devices: Improves Audibility for Those Communicating with Someone Wearing a Face Covering & No More Lip Reading

“The hearing challenges presented by face masks became obvious pretty quickly into the pandemic, so Signia developed the first-of-its-kind Face Mask Mode to help those with hearing loss better communicate in this new reality,” said Tish Ramirez, Au.D. of Signia. “When this setting is activated, the hearing aids optimally capture the sound of the speech signals, enabling the words to sound clearer and reducing any background noise to help the wearer understand what is being said.” 

Daniel Messina Appointed to Semler Scientific’s Board of Directors

Daniel Messina, an experienced and well-regarded health services executive and entrepreneur, has been appointed to Semler Scientific’s Board of Directors, effective August 13, 2020. With this addition, Semler’s Board now totals four members.

“Dan’s insights and industry knowledge will be invaluable assets to the Semler Board as he is a respected senior executive with nearly 40 years of business experience as both a healthcare system professional and a technology solutions entrepreneur,” stated Douglas Murphy-Chutorian, M.D., chief executive officer of Semler Scientific. “We welcome Dan to our Board and expect to leverage his significant industry expertise and proven leadership capabilities, as we continue to plan and execute on our growth goals, including the development and commercialization of additional proprietary products and services that make a meaningful impact on the evaluation of patients with chronic diseases.”

Daniel Messina is the co-founder of HandsFree Health, the creator of WellBe®, the premier voice-enabled virtual health assistant platform designed to help individuals access their health and wellness resources from home. Prior to co-founding HandsFree Health in 2016, he was co-president of West Corporation’s health advocate division for ten years. From 2002 to 2006, Mr. Messina was the president of Rendina Healthcare Real Estate. Before that, from 2000 to 2002, Mr. Messina served as chief executive officer and president of Magellan Health and from 1998 to 2000 as the chief financial officer and head of business strategy of Aetna Health. For the decade prior to that, he was vice president of Financial Reporting at Cigna Corporation.  Mr. Messina began his career as a certified public accountant at Deloitte.  Mr. Messina earned a Bachelor of Science in accounting from the University of Notre Dame.

Latest Posts

Philips to Introduce Latest Advancements In Digital Pathology at the European Congress of Pathology 2020 Virtual Event

Building on its strong portfolio to support oncology clinical decision-making, the company brings together the power of imaging, pathology, genomics, and longitudinal data with insights from artificial intelligence, to empower clinicians to deliver clear care pathways with predictable outcomes for every patient.

Zenith Award from American Association for Respiratory Care for Support of Respiratory Therapists Is Awarded to Vapotherm

Award celebrates excellence in support and quality as chosen by AARC member votes

Fusion Antibodies and Queen’s University Belfast Awarded a £453,000 Grant from Invest Northern Ireland

The two organisations will use the funds to accelerate the discovery of novel therapeutic and diagnostic antibodies with validated anti-infective properties against COVID-19. Building on strong scientific knowhow, a new antibody development platform will be created that will help realise the vision of producing a breakthrough therapeutic that directly targets SARS-CoV-2.

Don't Miss

New England Biolabs® Introduces NEBNext® Custom RNA Depletion Design Tool and RNA Depletion Core Reagent Set for Customizable RNA Depletion

This technology has been superb for eliminating the ribosomal RNA for a range of custom projects, including tracking novel viruses in mosquitoes, longitudinal profiling for astronauts, and host-pathogen interactions in COVID samples.

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

"FDA approval of the INTERCEPT Blood System for Cryoprecipitation is an important step forward in our mission to establish pathogen reduction as the standard of care for transfused blood components globally," said William ‘Obi’ Greenman, Cerus’ president and chief executive officer.

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Led by the Wuxi municipal government and administered by the National Cancer Center in China, the “Liver Cancer Early Screening Comprehensive Prevention and Control Project” is a public health initiative.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.